长链非编码RNA在前列腺癌治疗抵抗中作用机制的研究进展

Research Progress of Long Non-coding RNA in the Therapeutic Resistance of Prostate Cancer

前列腺癌(prostate cancer,PCa)是男性泌尿系统中最常见的恶性肿瘤,早期临床表现相对隐匿,不易诊断,中晚期常伴远处转移,预后较差。目前,治疗抵抗是临床治疗前列腺癌患者的主要难题,也是患者复发率高、预后差的重要原因。近年研究显示,长链非编码RNA(long non-coding RNA,LncRNA)与前列腺癌治疗抵抗密切相关,参与前列腺癌内分泌治疗药物耐药、化疗抵抗、免疫耐受和放疗抵抗,有望成为前列腺癌治疗抵抗的新靶标。因此,该文就LncRNA在前列腺癌治疗抵抗中的发生机制和潜在的临床应用作一综述,为解决前列腺癌治疗抵抗提供新思路。

Prostate cancer(PCa)is the most common malignant tumor in the male urinary system.The early clinical manifestations are relatively insidious and difficult to diagnose,and the middle and late stages are often accompanied by distant metastasis,and the prognosis is poor.At present,treatment resistance is a major problem in clinical treatment of prostate cancer patients,and also an important reason for the high recurrence rate and poor prognosis of patients.Recent studies have shown that long non-coding RNA is closely related to prostate cancer treatment resistance,and is involved in endocrine therapy drug resistance,chemotherapy resistance,immune tolerance and radiotherapy resistance of prostate cancer,which is expected to become a new target for prostate cancer treatment resistance.Therefore,this paper reviews the pathogenesis and potential clinical application of long non-coding RNA in prostate cancer treatment resistance,providing new ideas for solving the problem of prostate cancer treatment resistance.